ArticleScientific reports2022
Prospective assessment using
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Quantitative detection of macrophage activation in osteosarcoma comparingScientific reports · 2026Article
- Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot study.Scientific reports · 2026Article
- Clinical significance of visual cardiacCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Baseline and earlyCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.Translational lung cancer research · 2024Review
- Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.International journal of molecular sciences · 2022Review
- The association of metabolic positron emission tomography/computed tomography parameters with survival in small cell lung cancer.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-programmed death-1 (PD-1) blockade is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, no appropriate modality exists for monitoring its therapeutic response immediately after initiation. Therefore, we aimed to elucidate the clinical relevance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.